Discounted Cash Flow (DCF) Analysis Levered
TRxADE HEALTH, Inc. (MEDS)
$0.448
-0.02 (-4.68%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 2.93 | 3.83 | 7.44 | 17.12 | 9.89 | 15.15 | 23.21 | 35.56 | 54.48 | 83.46 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | 0.17 | 0.27 | 0.14 | -2.21 | -2.57 | -0.73 | -1.11 | -1.71 | -2.61 | -4 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | -0.02 | -0.08 | -0.04 | -0.02 | -0.07 | -0.11 | -0.17 | -0.26 | -0.41 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | 0.17 | 0.26 | 0.06 | -2.25 | -2.59 | -0.80 | -1.23 | -1.88 | -2.88 | -4.41 |
Weighted Average Cost Of Capital
| Share price | $ 0.448 |
|---|---|
| Beta | 1.176 |
| Diluted Shares Outstanding | 8.14 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 1.89% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.068 |
| Total Debt | 1.25 |
| Total Equity | 3.65 |
| Total Capital | 4.89 |
| Debt Weighting | 25.51 |
| Equity Weighting | 74.49 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 2.93 | 3.83 | 7.44 | 17.12 | 9.89 | 15.15 | 23.21 | 35.56 | 54.48 | 83.46 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 0.17 | 0.27 | 0.14 | -2.21 | -2.57 | -0.73 | -1.11 | -1.71 | -2.61 | -4 |
| Capital Expenditure | - | -0.02 | -0.08 | -0.04 | -0.02 | -0.07 | -0.11 | -0.17 | -0.26 | -0.41 |
| Free Cash Flow | 0.17 | 0.26 | 0.06 | -2.25 | -2.59 | -0.80 | -1.23 | -1.88 | -2.88 | -4.41 |
| WACC | ||||||||||
| PV LFCF | -0.70 | -0.99 | -1.42 | -2.03 | -2.90 | |||||
| SUM PV LFCF | -8.62 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.24 |
| Free cash flow (t + 1) | -4.50 |
| Terminal Value | -85.84 |
| Present Value of Terminal Value | -60.52 |
Intrinsic Value
| Enterprise Value | -69.14 |
|---|---|
| Net Debt | -1.87 |
| Equity Value | -67.27 |
| Shares Outstanding | 8.14 |
| Equity Value Per Share | -8.27 |